Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Other Items
Entrada Therapeutics Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Other Items
-$24.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Entrada Therapeutics Inc
Glance View
Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.
See Also
What is Entrada Therapeutics Inc's Other Items?
Other Items
-24.6m
USD
Based on the financial report for Dec 31, 2024, Entrada Therapeutics Inc's Other Items amounts to -24.6m USD.
What is Entrada Therapeutics Inc's Other Items growth rate?
Other Items CAGR 1Y
81%
Over the last year, the Other Items growth was 81%.
